ResMed CEO Michael J. Farrell sells $1.84 million in stock

SAN DIEGO—Michael J. Farrell, Chief Executive Officer of ResMed Inc . (NYSE:RMD), a $33.6 billion market cap company with a perfect Piotroski Score of 9 according to InvestingPro, recently sold shares of the company’s stock valued at approximately $1.84 million. This transaction was executed under a pre-arranged trading plan, known as a Rule 10b5-1 plan, adopted on October 31, 2024.

The sale, which took place on March 7, 2025, involved 8,009 shares of ResMed common stock at an average price of $229.20 per share, with prices ranging from $223.64 to $232.39. Following the sale, Farrell retains direct ownership of 455,472 shares. Based on InvestingPro’s Fair Value analysis, the stock currently shows modest upside potential.

In addition to the stock sale, Farrell exercised options to acquire 8,009 shares at a price of $101.64 per share, amounting to a total acquisition value of $814,034. These options were initially granted on November 11, 2019, and vested in equal annual installments over three years.

Farrell also maintains indirect ownership of 2,090 shares through the Lisette and Michael Farrell Family Trust. The transactions reflect Farrell’s continued management of his equity holdings in ResMed, a leading provider of medical devices and cloud-connected solutions for people with sleep apnea and other chronic respiratory conditions.

In other recent news, ResMed reported its Q2 FY2025 earnings, surpassing analyst expectations with an earnings per share (EPS) of $2.43, compared to the forecast of $2.32. The company also exceeded revenue projections, posting $1.28 billion against the anticipated $1.27 billion. Despite these strong results, ResMed’s stock experienced a decline in after-hours trading. Meanwhile, Citi analysts upgraded ResMed’s stock rating from Neutral to Buy, setting a new price target of AUD44.00, citing the company’s strong expected EPS growth and financial stability. In contrast, Stifel analysts expressed concerns about the CPAP market due to the growing use of GLP-1 drugs, reducing their price target for ResMed to $240 while maintaining a Hold rating. Additionally, ResMed was added to Goldman Sachs’ APAC Director’s Cut Conviction List, highlighting a positive outlook based on expected patient growth and market expansion. These developments offer a multifaceted view of ResMed’s current position and future prospects in the market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.